CLYM (Climb Bio) Forward PE Ratio: 0.00 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLYM Climb Bio Inc CLYM
22 GF Score
Price $12.58
! 2 Warning Signs
View Full Analysis

What is Climb Bio Forward PE Ratio?

Climb Bio CLYM 22 Forward PE Ratio is 0.00 as of Jul. 17, 2026. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 354 Biotechnology companies, Climb Bio ranks worse than 282485.59% on this metric.

Climb Bio's Forward PE Ratio for today is 0.00.

Climb Bio's PE Ratio without NRI for today is 0.00.

Climb Bio's PE Ratio (TTM) for today is 0.00.

Climb Bio  (NAS:CLYM) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Climb Bio Forward PE Ratio Related Terms

Climb Bio Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Climb Bio's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Climb Bio Forward PE Ratio Chart

Climb Bio Annual Data
Trend
Forward PE Ratio

Climb Bio Quarterly Data
Forward PE Ratio

CLYM vs XOMA, CTMX, ALLO: Forward PE Ratio Comparison

For the Biotechnology subindustry, Climb Bio's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Climb Bio Forward PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Climb Bio's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Climb Bio's Forward PE Ratio falls into.


CLYM
22GF Score
Climb Bio Inc CLYM
Forward PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Climb Bio Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.00 mean?
Climb Bio (CLYM) has a Forward PE Ratio of 0.00 as of Jul. 17, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Climb Bio and its competitors. According to the industry distribution chart, Climb Bio ranks #999999 out of 354 companies in the Biotechnology industry.
Is Climb Bio's Forward PE Ratio too high?
Climb Bio's current Forward PE Ratio is 0.00. Based on the distribution chart, Climb Bio ranks #999999 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's Forward PE Ratio compare to XOMA and CTMX?
According to the Biotechnology industry distribution chart, Climb Bio ranks #999999 out of 354 companies for Forward PE Ratio. This places Climb Bio in the lower half of its industry. The industry median Forward PE Ratio is 21.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.97, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Climb Bio and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Climb Bio's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current Forward PE Ratio of 0.00. The current Forward PE Ratio is 0.00. Climb Bio's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Climb Bio (CLYM), the current Forward PE Ratio is 0.00 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Climb Bio Business Description

Address 20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score

Get the complete analysis for CLYM

Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.58
Price